{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T10:44:26Z","timestamp":1785926666145,"version":"3.56.0"},"reference-count":37,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010722","name":"Harbin Medical University","doi-asserted-by":"publisher","award":["HYDSYYXQN202511"],"award-info":[{"award-number":["HYDSYYXQN202511"]}],"id":[{"id":"10.13039\/100010722","id-type":"DOI","asserted-by":"publisher"}]},{"award":["HYDSYYXQN202511"],"award-info":[{"award-number":["HYDSYYXQN202511"]}],"id":[{"id":"https:\/\/ror.org\/05jscf583","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background: Despite recent advances in reperfusion strategies, acute coronary syndrome (ACS) patients remain at high risk for recurrent major adverse cardiovascular events (MACE). This study aims to investigate the association between lipoprotein(a) (Lp(a)) and MACE in ACS patients, and to systematically evaluate its predictive performance, incremental prognostic value and clinical utility. Methods: This retrospective cohort study included 300 ACS patients with a 1-year follow-up. Serum Lp(a) levels were measured by immunoturbidimetry using fasting venous blood samples collected on the day of admission. Kaplan\u2013Meier and Cox regression analyses were used to assess the association between Lp(a) and MACE. Subgroup and interaction analyses were performed to test the robustness of the findings. Incremental predictive value and net clinical benefit were evaluated using receiver operating characteristic (ROC) curves, the DeLong test, decision curve analysis (DCA) and the integrated discrimination improvement (IDI) index. Results: Baseline Lp(a) levels were significantly higher in the event group (p = 0.006). A significantly lower cumulative survival probability was found in patients with elevated Lp(a) (log-rank p = 0.0014). As a standalone predictor of MACE, Lp(a) yielded an AUC of 0.606 (p = 0.006). The AUC of the baseline model was 0.753 (95% CI: 0.694\u20130.812), which increased to 0.771 (95% CI: 0.712\u20130.831) after adding Lp(a). DCA showed that the Lp(a)-guided strategy provided higher net benefit than both the \u201ctreat-all\u201d and \u201ctreat-none\u201d strategies within a threshold probability range of 0\u20130.35. Conclusions: Although Lp(a) offers limited incremental value over traditional risk factors and the Gensini score in the low-to-moderate risk range (&lt;0.35), it provides net clinical benefit as a complementary biomarker in ACS.<\/jats:p>","DOI":"10.3390\/jcm15156086","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T09:16:22Z","timestamp":1785921382000},"page":"6086","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lipoprotein(a) as a Predictor of Major Adverse Cardiovascular Events in Patients with Acute Coronary Syndrome"],"prefix":"10.3390","volume":"15","author":[{"given":"Xinhang","family":"Li","sequence":"first","affiliation":[{"name":"Department of Cardiology, The Fourth Afffliated Hospital of Harbin Medical University, Harbin 150001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huidi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Fourth Afffliated Hospital of Harbin Medical University, Harbin 150001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxu","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Fourth Afffliated Hospital of Harbin Medical University, Harbin 150001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Fourth Afffliated Hospital of Harbin Medical University, Harbin 150001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyu","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Fourth Afffliated Hospital of Harbin Medical University, Harbin 150001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"ref_1","first-page":"891","article-title":"Cardiovascular Health and Disease Report in China: Two Decades of Progress","volume":"38","author":"Su","year":"2025","journal-title":"Biomed. Environ. Sci."},{"key":"ref_2","first-page":"e41","article-title":"2025 Heart Disease and Stroke Statistics: A Report of US and Global Data from the American Heart Association","volume":"151","author":"Martin","year":"2025","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Li, Y., Wu, J., Xu, Y., Dong, J., Xing, B., Wang, Y., Zhou, Z., Sun, B., Li, J., and Yu, L. (2025). Cold exposure and the cardiovascular system: From physiological adaptation to pathological risk. Front. Physiol., 16.","DOI":"10.3389\/fphys.2025.1740919"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1515\/med-2022-0584","article-title":"Inhibition of miR-21 improves pulmonary vascular responses in bronchopulmonary dysplasia by targeting the DDAH1\/ADMA\/NO pathway","volume":"17","author":"Zhong","year":"2022","journal-title":"Open Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e672","DOI":"10.1016\/S2468-2667(20)30191-2","article-title":"Cardiovascular risk factors in China: A nationwide population-based cohort study","volume":"5","author":"Li","year":"2020","journal-title":"Lancet Public Health"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Buonpane, A., De Caterina, A.R., Trimarchi, G., Pizzino, F., Ciardetti, M., Coceani, M.A., Esposito, A., Pastormerlo, L.E., Monteleone, A., and Clemente, A. (2025). Uncovering Plaque Erosion: A Distinct Pathway in Acute Coronary Syndromes and a Gateway to Personalized Therapy. J. Clin. Med., 14.","DOI":"10.3390\/jcm14155456"},{"key":"ref_7","first-page":"939","article-title":"Acute LDL-C reduction post ACS: Strike early and strike strong: From evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy","volume":"11","author":"Krychtiuk","year":"2022","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1016\/j.jacc.2026.03.069","article-title":"Lipid-Lowering Therapy in the 2026 ACC\/AHA\/Multisociety Guideline on the Management of Dyslipidemia: A Perspective from China","volume":"87","author":"Li","year":"2026","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Yun, H.R., Singh, M.K., Han, S., Ranbhise, J.S., Ha, J., Kim, S.S., and Kang, I. (2026). Lipoprotein(a) and Cardiovascular Disease: From Genetic Risk Factor to Therapeutic Target. Cells, 15.","DOI":"10.3390\/cells15040315"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/MOL.0000000000001000","article-title":"The complex pro-atherosclerotic role of lipoprotein(a): A multiplicity of cellular targets","volume":"36","author":"Assini","year":"2025","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/MCA.0000000000000940","article-title":"Lipoprotein(a) as a predictor for the presence and severity of premature coronary artery disease: A cross-sectional analysis of 2433 patients","volume":"32","author":"Shi","year":"2021","journal-title":"Coron. Artery Dis."},{"key":"ref_14","first-page":"e90747","article-title":"Lipoprotein(a) as an Independent Biomarker of Coronary Complexity: Prevalence, Clinical Correlates, and Diagnostic Utility in a North Indian Acute Coronary Syndrome Cohort","volume":"17","author":"Mahajan","year":"2025","journal-title":"Cureus"},{"key":"ref_15","first-page":"1428","article-title":"Interpretation of the 2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the management of patients with acute coronary syndromes","volume":"53","author":"Li","year":"2025","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"101549","DOI":"10.1016\/j.jacadv.2024.101549","article-title":"Impact of Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibitors on Lipoprotein(a): A Meta-Analysis and Meta-Regression of Randomized Controlled Trials","volume":"4","author":"Rivera","year":"2025","journal-title":"JACC Adv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e014129","DOI":"10.1161\/JAHA.119.014129","article-title":"Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies","volume":"9","author":"Toth","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.2147\/IJGM.S495194","article-title":"The Gensini Score System is a Useful Tool in Assessing the Burden and Severity of Coronary Artery Atherosclerotic Lesions [Letter]","volume":"17","author":"Naser","year":"2024","journal-title":"Int. J. Gen. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"g7594","DOI":"10.1136\/bmj.g7594","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement","volume":"350","author":"Collins","year":"2015","journal-title":"BMJ"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1136\/heartjnl-2020-316586","article-title":"Association of lipoprotein(a) levels with recurrent events in patients with coronary artery disease","volume":"106","author":"Liu","year":"2020","journal-title":"Heart"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/j.jcin.2021.07.042","article-title":"Association of Lipoprotein(a) with Recurrent Ischemic Events Following Percutaneous Coronary Intervention","volume":"14","author":"Yoon","year":"2021","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Wang, G., Xia, M., Liang, C., Pu, F., Liu, S., and Jia, D. (2024). Prognostic value of elevated lipoprotein (a) in patients with acute coronary syndromes: A systematic review and meta-analysis. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1362893"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"42784","DOI":"10.31083\/RCM42784","article-title":"Lipoprotein(a) as a Predictor of Cardiovascular Risk in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review","volume":"26","author":"Mojahedi","year":"2025","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Qin, K., and Zhang, T. (2025). Lipoprotein(a) and its linear association with all-cause and cardiovascular mortality in patients with acute coronary syndrome. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1580298"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.3346\/jkms.2023.38.e102","article-title":"Baseline Lipoprotein(a) Levels and Long-Term Cardiovascular Outcomes After Acute Myocardial Infarction","volume":"38","author":"Park","year":"2023","journal-title":"J. Korean Med. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41598-025-86154-0","article-title":"The nonlinear association between lipoprotein(a) and major adverse cardiovascular events in acute coronary syndrome patients with three-vessel disease","volume":"15","author":"Li","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Jung, H.W., Hong, S.P., and Kim, K.S. (2021). Comparison of apolipoprotein B\/A1 ratio, TC\/HDL-C, and lipoprotein (a) for predicting outcomes after PCI. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0254677"},{"key":"ref_28","first-page":"e62984","article-title":"Lipoprotein(a)\u2019s Role in Atherosclerosis and Aortic Stenosis: A Contemporary Literature Review","volume":"16","author":"Obi","year":"2024","journal-title":"Cureus"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"123586","DOI":"10.1016\/j.ijbiomac.2023.123586","article-title":"Exploring the role of lipoprotein(a) in cardiovascular diseases and diabetes in Chinese population","volume":"233","author":"Hussain","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"120516","DOI":"10.1016\/j.atherosclerosis.2025.120516","article-title":"Lipoprotein(a) concentrations and secondary outcomes following first-time acute coronary syndrome: The Multi-Ethnic New Zealand Study of Acute Coronary Syndromes (MENZACS)","volume":"410","author":"Legget","year":"2025","journal-title":"Atherosclerosis"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Phan, H.T., and Ho, M.T.T. (2025). Value of lipoprotein(a) in predicting severity of coronary artery stenosis in patients with chronic coronary artery disease: A cross-sectional study in Vietnam. Front. Cardiovasc. Med., 12.","DOI":"10.3389\/fcvm.2025.1669234"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1001\/jamacardio.2025.1603","article-title":"AHA PREVENT Equations and Lipoprotein(a) for Cardiovascular Disease Risk: Insights from MESA and the UK Biobank","volume":"10","author":"Bhatia","year":"2025","journal-title":"JAMA Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Fathieh, S., Tang, O., Gray, M.P., Zanchin, C., Vernon, S.T., Genetzakis, E., Tran, C., Sullivan, D.R., Nicholls, S.J., and Celermajer, D.S. (2025). Evaluating the Role of Lipoprotein(a) in Enhancing Risk Stratification for the Presence and Extent of Subclinical Coronary Artery Disease Burden\u2014A BioHEART-CT Study. Eur. J. Prev. Cardiol., zwaf323.","DOI":"10.1093\/eurjpc\/zwaf323"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.jacc.2024.03.370","article-title":"Lipoprotein(a), Residual Cardiovascular Risk, and the Search for Targeted Therapy","volume":"83","author":"Blaha","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Hu, J., Wang, J., Zhang, H., Jiang, Y., Deng, L., Long, E., and Liu, S. (2026). Efficacy and safety of lipoprotein(a)-targeted therapeutics: A systematic review and network meta-analysis. Front. Cardiovasc. Med., 13.","DOI":"10.3389\/fcvm.2026.1758366"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering with Pelacarsen on Major Cardiovascular Events in Patients with CVD and Elevated Lp(a)","volume":"287","author":"Cho","year":"2025","journal-title":"Am. Heart J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"87","author":"Blumenthal","year":"2026","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/15\/6086\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T09:50:56Z","timestamp":1785923456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/15\/6086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":37,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["jcm15156086"],"URL":"https:\/\/doi.org\/10.3390\/jcm15156086","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]}}}